Researchers at Oregon State University have made a groundbreaking advancement in the fight against glioblastoma, the most aggressive and deadly form of brain cancer. Glioblastoma’s grim prognosis—fewer than 30% of patients survive beyond two years after diagnosis—has long challenged oncologists and researchers alike. The new study, led by Oleh Taratula, Olena Taratula, and Yoon Tae Goo from the OSU College of Pharmacy, offers a promising therapeutic approach that significantly extends survival by overcoming two of the most daunting obstacles in glioblastoma treatment: traversing the blood-brain barrier (BBB) and selectively targeting tumor cells.
The blood-brain barrier, a highly selective semipermeable membrane of endothelial cells, protects the brain by filtering out potentially harmful substances circulating in the bloodstream while allowing only essential nutrients to pass. Unfortunately, this protective barrier also blocks many therapeutic agents, making effective drug delivery to brain tumors notably difficult. In their study published in the Journal of Controlled Release, the researchers innovatively engineered lipid nanoparticles to carry therapeutic mRNA molecules and coat them with a sugar molecule—mannose—that cleverly exploits natural nutrient transport mechanisms to cross the BBB.
Their strategy harnesses the brain endothelium’s GLUT1 transporter, a protein embedded in the blood vessel lining dedicated to the uptake of glucose, the brain’s chief energy source. Mannose, a sugar structurally similar to glucose, can also be recognized and transported by GLUT1. By densely coating lipid nanoparticles with mannose chemically linked to cholesterol, the researchers drastically improved the particles’ ability to hijack this transporter and slip through the blood-brain barrier. This molecular camouflage represents a novel breakthrough that elevates the efficiency of nanoparticle transport into the central nervous system.
Inside these mannose-coated nanoparticles, the scientists encapsulated messenger RNA encoding PTEN, a tumor suppressor protein that is commonly lost or mutated in glioblastoma cells. PTEN plays a critical role in regulating cellular growth and preventing malignancy. By restoring PTEN expression, the therapeutic mRNA triggers mechanisms that inhibit tumor proliferation and promote cancer cell death. To protect the fragile mRNA payload during delivery, they also incorporated a cationic cholesterol derivative, which enhances encapsulation stability and ensures the therapeutic’s integrity upon reaching its target.
This dual-targeting approach proved strikingly effective in a rigorous mouse model of glioblastoma. Treated animals experienced a 50% increase in median survival time compared to controls, a remarkable milestone given glioblastoma’s notorious resistance to conventional therapies. Tumors showed significant shrinkage after repeated dosing, and importantly, there was no detectable toxicity to other organs. The approach combines specificity and potency, minimizing collateral damage—a frequent limitation of systemic cancer treatments.
The researchers highlight that glioblastoma cells exhibit elevated GLUT1 expression—approximately threefold higher than normal brain tissue—which facilitates selective nanoparticle accumulation in tumor regions after crossing the blood-brain barrier. This metabolic reprogramming of glioblastoma not only supports tumor growth but also inadvertently provides a therapeutic window for targeted delivery systems exploiting glucose transport pathways. This innovative exploitation of tumor physiology underscores a shift toward smarter, more precise nanomedicine treatments.
Though glioblastoma is relatively rare with an incidence rate of 3.19 per 100,000 people in the United States, its devastating prognosis and rapid progression necessitate urgent intervention strategies. Affecting men more frequently than women and typically diagnosed around age 64, glioblastoma’s five-year survival rate plunges below 5%. The urgent clinical need drives continued research into novel therapies capable of improving outcomes and quality of life for this vulnerable population.
The multidisciplinary study team included Vincent Cataldi, Vladislav Grigoriev, Neera Yadav, Tetiana Korzun, Chao Wang, and Adam Alani, alongside the lead investigators. Their collective expertise spanned nanotechnology, pharmacology, molecular biology, and oncology, enabling the comprehensive design and testing of these multifunctional nanoparticles. Funding and support came from prestigious bodies including the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea.
This study’s success establishes a promising platform for advancing mRNA-based therapeutics beyond glioblastoma. The foundational innovation—using a single ligand, mannose, to achieve dual targeting of crossing the BBB and preferential tumor accumulation—could be adapted for other neurological diseases requiring delivery of genetic medicine to the brain. The ability to deliver functional mRNA payloads securely and efficiently represents an exciting frontier in personalized medicine.
Future research will undoubtedly focus on scaling up this approach, optimizing dosing regimens, and eventually translating these findings into clinical trials in humans. Safety profiles observed in animal models are encouraging, but further studies are essential to fully understand long-term effects, potential immune responses, and therapeutic durability. The OSU team’s pioneering work paves the way for new hope in the relentless battle against a cancer that has defied treatment for decades.
In summary, this novel nanomedicine strategy addresses the fundamental challenges that have long hindered glioblastoma therapy: surmounting the blood-brain barrier and selectively delivering tumor-suppressing genetic material. By leveraging the naturally high GLUT1 activity in glioblastoma and innovatively coating lipid nanoparticles with mannose, the research delivers therapeutic mRNA encoding PTEN, restoring tumor inhibition and prolonging survival in preclinical models. This milestone could herald a new era of effective brain cancer treatments grounded in nanotechnology and molecular precision.
Subject of Research: Animals
Article Title: Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier
News Publication Date: 18-Jun-2026
Web References: http://dx.doi.org/10.1016/j.jconrel.2026.115107
References: Journal of Controlled Release
Image Credits: Parinaz Ghanbari
Keywords: glioblastoma, blood-brain barrier, lipid nanoparticles, mRNA therapy, PTEN, nanomedicine, GLUT1 transporter, mannose coating, targeted drug delivery, brain cancer, tumor suppression, nanotechnology
Tags: advanced brain cancer therapeuticsblood-brain barrier drug deliveryglioblastoma treatment breakthroughsGLUT1 transporter drug deliverymannose-coated lipid nanoparticlesmRNA therapy for brain cancernanotechnology in oncologyOregon State University glioblastoma researchovercoming blood-brain barrier challengesselective tumor targeting strategiessugar-coated nanoparticlestargeting brain tumor cells
